Olmesartan Medoxomil in Elderly Patients with Essential or Isolated Systolic Hypertension

A. Heagerty,J. Mallion

DOI: https://doi.org/10.2165/0002512-200926010-00005

2009-01-01

Drugs & Aging

Abstract:

What problem does this paper attempt to address?

Clinical Study of Olmesartan/hydrochlorothiazide Compound Tablet in Mild to Moderate Essential Hypertensive Patients Who Did Not Reach Goal with Olmesartan

ZHU Ding-liang,CAI Nai-sheng,HE Ben,WU Zong-gui,WEI Meng,KE Yuan-nan,SUN Ning-ling,HUA Qi,YE Ping,HE Guo-xiang,ZHU Shan-jun,ZENG Zhi,MA Hong,CHEN Jun-zhu,HUANG Jun,LI Xin-li,LIAO Yu-hua,ZHU Jun-ren

DOI: https://doi.org/10.16439/j.cnki.1673-7245.2011.02.029

2011-01-01

Abstract:Objective To evaluate the efficacy and safety of olmesartan medoxomil/hydrochlorothiazide 20/12.5 mg in mild to moderate essential hypertensive patients who did not reach goal with olmesartan medoxomil 20 mg monotherapy.Methods This was a multi-center,randomized,double-blind and double dummy,active-controlled design study.The trial enrolled 438 participants with mild to moderate hypertension.After 2 weeks of placebo run-in period,380 participants were treated with olmesartan medoxomil 20 mg/d for 4 weeks.At the end of this period,304 patients who did not respond to monotherapy mean sitting diastolic blood pressure(MSDBP)≥90 mm Hg)] were randomized to 8 weeks' double-blind treatment with olmesartan medoxomil/hydrochlorothiazide 20/12.5 mg(compound tablet)daily or olmesartan medoxomil 40 mg(monotherapy)daily.Results Compared with baseline,the decrease of mean sitting systolic blood pressure(MSSBP)and MSDBP of olmesartan/hydrochlorothiazide group(14.8/11.9 mm Hg)were significantly more than monotherapy group(9.0/9.0 mm Hg)at 8 weeks(P 0.01).The total efficacy rate of olmesartan/hydrochlorothiazide group(84.1%)were significantly higher than olmesartan
Efficacy and Safety of Sacubitril/Valsartan (LCZ696) Compared with Olmesartan in Elderly Asian Patients (≥65 Years) with Systolic Hypertension.

Ouppatham Supasyndh,Jian'an Wang,Kudsia Hafeez,Ying Zhang,Jack Zhang,Hiromi Rakugi

DOI: https://doi.org/10.1093/ajh/hpx111

2017-01-01

American Journal of Hypertension

Abstract:OBJECTIVE Systolic hypertension is common in elderly patients and remains a challenge to treat effectively. The efficacy and safety of sacubitril/valsartan (LCZ696), a first-in-class angiotensin receptor neprilysin inhibitor, vs. olmesartan was evaluated in elderly Asian patients (>= 65 years) with systolic hypertension. METHODS In this randomized, double-blind, 14-week study, patients initially received once-daily sacubitril/valsartan 100 mg or olmesartan 10 mg, increased to sacubitril/valsartan 200 mg or olmesartan 20 mg at week 4. At week 10, for patients with blood pressure (BP) > 140/90 mm Hg, the doses were up-titrated to sacubitril/valsartan 400 mg or olmesartan 40 mg. The primary assessment was superiority of sacubitril/valsartan vs. olmesartan in reducing office mean sitting (ms) systolic BP (msSBP) from baseline at week 10. Secondary efficacy assessments included changes from baseline in ms diastolic BP (msDBP), ms pulse pressure (msPP), 24-hour mean ambulatory (ma) BP (maBP), and maPP at week 10; msBP and msPP at weeks 4 and 14. RESULTS Overall, 588 patients were randomized (mean age, 70.7 years; baseline msBP, 160.3/84.9 mm Hg; msPP, 75.4 mm Hg). At week 10, sacubitril/valsartan provided superior msSBP reductions vs. olmesartan (22.71 vs. 16.11 mm Hg, respectively; P < 0.001); similarly, reductions from baseline in other BP and PP assessments were significantly greater with sacubitril/valsartan. At week 14, despite more patients requiring up-titration in the olmesartan group, msBP and msPP reductions from baseline were significantly greater with sacubitril/valsartan. Both treatments were generally well-tolerated. CONCLUSION Sacubitril/valsartan is more effective than olmesartan in reducing BP in elderly Asian patients with systolic hypertension.
Efficacy and Safety of Olmesartan Medoxomil‑amlodipine Besylate Tablets (sevikar®) in Older Patients with Essential Hypertension: Subgroup Analysis from the Sevikar Study.

Zhaoqiang Cui,Zhaohui Qiu,Wenli Cheng,Wei Hu,Genshan Ma,Xiaojun Cai,Yafei Jin,Yi Zhao,Liqun He,Ying Li,Peili Bu,Xiaoping Chen,Ruxing Wang,Lin Chen,Peng Dong,Liuliu Feng,Xuebin Han,Mei Hong,Yinglong Hou,Minlei Liao,Mingliang Wang,Xiaoyan Wang,Jianhong Xie,Yawei Xu,Zhenxing Wang,Kai Huang,Yongle Li,Dongsheng Li,Xiaojun Ji,Jing Huang,Jun Wang,Danhong Fang,Jian'an Wang,Lijiang Tang,Yingwu Liu,Guosheng Fu,Juan Du,Ling Wang,Mengqi Liu,Junbo Ge

DOI: https://doi.org/10.3892/etm.2023.12338

IF: 2.7

2024-01-01

Experimental and Therapeutic Medicine

Abstract:Essential hypertension is a notable threat for the older (age, >= 65 years) population. However, to the best of our knowledge, a real-world study assessing olmesartan medoxomil-amlodipine besylate (OM-AML) tablets in older Chinese patients with essential hypertension has not been performed. Therefore, the present study aimed to evaluate the efficacy and safety of OM-AML tablets in these patients. A total of 463 older Chinese patients with essential hypertension treated with OM-AML (20/5 mg) tablets (Sevikar (R)) were analyzed in a prospective, single-arm, multi-center, real-world study. Seated systolic blood pressure (SeSBP) and seated diastolic blood pressure (SeDBP) at baseline, and at week (W)4 and W8 after OM-AML tablet administration were measured. The mean +/- standard error change of SeSBP/SeDBP was -10.3 +/- 0.8/-4.6 +/- 0.5 and -12.5 +/- 0.8/-5.6 +/- 0.5 mmHg at W4 and W8, respectively. At W4, 74.1 and 26.8% of patients achieved BP target according to the China and American Heart Association (AHA) criteria, while at W8, 78.0 and 38.7% of patients reached these BP targets accordingly. Finally, 76.5 and 80.5% of patients achieved BP response at W4 and W8, respectively. Furthermore, home-measured SeSBP and SeDBP were significantly decreased from W1 to W8 (both P<0.001). Additionally, the satisfaction of both patients and physicians was elevated at W8 compared with at W0 (both P<0.001). The medication possession rate from baseline to W4 and W8 was 95.5 and 92.5%. The most common drug-associated adverse events by system organ classes were nervous system disorder (4.5%), vascular disorder (2.8%), and general disorder and administration site conditions (2.6%), which were generally mild. In conclusion, OM-AML tablets may be considered effective and safe in lowering BP, enabling the achievement of guideline-recommended BP targets in older Chinese patients with essential hypertension.
Efficacy and Safety of Olmesartan Medoxomil-Amlodipine Besylate Tablet in Chinese Patients with Essential Hypertension: A Prospective, Single-Arm, Multi-Center, Real-World Study

Zhaoqiang Cui,Zhaohui Qiu,Wenli Cheng,Wei Hu,Genshan Ma,Xiaojun Cai,Yafei Jin,Yi Zhao,Liqun He,Ying Li,Peili Bu,Xiaoping Chen,Ruxing Wang,Lin Chen,Peng Dong,Liuliu Feng,Xuebin Han,Mei Hong,Yinglong Hou,Minlei Liao,Mingliang Wang,Xiaoyan Wang,Jianhong Xie,Yawei Xu,Zhenxing Wang,Kai Huang,Yongle Li,Dongsheng Li,Xiaojun Ji,Jing Huang,Jun Wang,Danhong Fang,Jian'an Wang,Lijiang Tang,Yingwu Liu,Guosheng Fu,Juan Du,Ling Wang,Mengqi Liu,Junbo Ge

DOI: https://doi.org/10.1111/jch.14700

2024-01-01

Journal of Clinical Hypertension

Abstract:There lacks real-world study with a large sample size assessing olmesartan medoxomil-amlodipine besylate (OM-AML) tablet. Therefore, this study aimed to evaluate the efficacy and safety of OM-AML tablet in patients with essential hypertension. Totally, 1341 patients from 36 medical centers with essential hypertension who took OM-AML (20/5 mg) tablet were analyzed in the current prospective, single-arm, multi-center, real-world study (SVK study). Seated systolic blood pressure (SeSBP) and seated diastolic blood pressure (SeDBP) at baseline, week (W)4 and W8 were measured. The mean (±SE) change of SeSBP/SeDBP was -10.8 ± 0.4/-6.6 ± 0.3 mmHg at W4 and -12.7 ± 0.5/-7.6 ± 0.3 mmHg at W8, respectively. At W4, 78.8% and 29.0% patients achieved BP target by China and American Heart Association (AHA) criteria; at W8, 84.7% and 36.5% patients reached blood pressure (BP) target by China and AHA criteria, accordingly. Meanwhile, 80.2% and 86.4% patients achieved BP response at W4 and W8, respectively. Home-measured SeSBP and SeDBP decreased from W1 to W8 (both p < .001). Besides, patients' and physicians' satisfaction were elevated at W8 compared with W0 (both p < .001). The medication possession rate was 94.8% from baseline to W4 and 91.3% from baseline to W8. The most common drug-related adverse events were nervous system disorders (4.6%), vascular disorders (2.6%), and general disorders and administration site conditions (2.3%) by system organ class, which were generally mild and manageable. In conclusion, OM-AML tablet is one of the best antihypertensive agents in patients with essential hypertension.
Efficacy of Olmesartan/Amlodipine Single‐Pill Combination on 24‐h Mean Systolic Blood Pressure Measured by Ambulatory Monitoring in Non‐Responders to Valsartan or Candesartan Monotherapy

Woo‐Baek Chung,Sang‐Hyun Ihm,Yun‐Seok Choi,Ho‐Joong Youn

DOI: https://doi.org/10.1111/jch.14929

2024-11-08

Journal of Clinical Hypertension

Abstract:The aim of this study was to evaluate the efficacy of olmesartan/amlodipine (OLM/AML) single‐pill combination (SPC) therapy using ambulatory blood pressure monitoring (ABPM) in non‐responders to valsartan or candesartan monotherapy. Isolated systolic hypertension (ISH) is the most prevalent form of hypertension in middle‐aged and elderly individuals. Patients aged over 55 years who did not achieve the target systolic blood pressure (SBP < 140 mmHg) with valsartan 80 mg or candesartan 8 mg for at least 4 weeks were included. Doses were escalated from 20/5 mg to 40/5 mg and finally to 40/10 mg of OLM/AML SPC until patients reached the target SBP. Efficacy was assessed via ABPM by comparing baseline values with those in the 12th week. Office blood pressure (OBP) and brachial‐ankle pulse wave velocity (baPWV) were assessed at baseline, weeks 4, 8, and 12. Fifty‐four patients (average age 64 ± 6 years; 33 males) participated. The 24‐h mean BPs decreased significantly from an average of 146.2 ± 12.7/93.3 ± 9.2 mmHg to 129.7 ± 14.3/83.4 ± 10.7 mmHg (p < 0.001), and pulse pressures (PPs) from ABPM were reduced (p < 0.001). Additionally, significant reductions in night‐time SBP standard deviations (SDs) (14.7 ± 4.7 vs. 12.5 ± 3.9, p = 0.029) were observed at 12 weeks compared to baseline. OBPs significantly dropped from 151.1 ± 9.7/89.3 ± 8.3 mmHg to 125.5 ± 13.8/77.8 ± 8.8 mmHg after 12 weeks of SPC therapy (p < 0.001). Reductions in PPs of OBP and baPWVs were also observed. OLM/AML SPC therapy effectively reduced the 24‐h mean BP, as measured by ABPM, in hypertensive patients over 55 years old who failed to achieve a target SBP (< 140 mmHg) with angiotensin receptor blocker (ARB) monotherapy using valsartan 80 mg or candesartan 8 mg. Trial Registration: ClinicalTrials.gov identifier: NCT01713920

peripheral vascular disease
The association between oxidative stress, activator protein-1, inflammatory, total antioxidant status and artery stiffness and the efficacy of olmesartan in elderly patients with mild-to-moderate essential hypertension

Qunwei Liu,Limin Han,Qiufan Du,Ming Zhang,Shenghua Zhou,Xiangqian Shen

DOI: https://doi.org/10.3109/10641963.2015.1131285

2016-05-09

Clinical and Experimental Hypertension

Abstract:This study investigated the change of oxidative stress, activator protein-1 (AP-1), inflammatory, total antioxidant status (TAS) and artery stiffness, and explored the relationship between these characteristics and the efficacy of olmesartan intervention in elderly patients with mild-to-moderate essential hypertension (EH). In total, 386 elderly patients with EH and 353 normotensive controls were recruited. All study subjects had oxidative stress markers, AP-1, inflammatory factors, TAS and brancial-ankle artery pulse wave velocity (ba-PWV) measured. In total, 193 elderly patients with EH were randomized to olmesartan and were matched with 193 normotensive controls to observe the change of index above mentioned before and after the treatment. Compared with the controls, superoxide dismutase (SOD) and TAS were significantly reduced in patients with EH, and malondialdehyde (MDA), AP-1, high-sensitivity C-reactive protein (Hs-CRP), Monocyte Chemoattractant Protein-1 (MCP-1), heart rate, endothelin-1 (ET-1), TAS and ba-PWV were significantly increased (P < 0.01 for all). Pearson's correlation analysis showed that SOD and TAS were negatively related to AP-1 (P < 0.05 for all), and that blood pressure (BP), age, MDA, Hs-CRP, MCP-1, ET-1 were positively related to AP-1 (P < 0.01 for all). Multivariate linear regression analysis showed that BP, SOD, MDA, AP-1, Hs-CRP, MCP-1, ET-1, TAS, heart rate and age were independent risk factors for ba-PWV. After treatment with olmesartan, SOD and TAS were increased, while BP, heart rate, AP-1 and inflammatory factors were reduced with significant improvement in ba-PWV (P < 0.05 for all). More increase of arterial stiffness was reported in elderly hypertensive patients with greater oxidative stress, inflammatory, AP-1, heart rate, and lower TAS. Higher oxidative stress, AP-1 and inflammatory may predict higher arterial stiffness. Olmesartan may increase TAS, yet inhibit oxidative stress, AP-1, inflammatory, and heart rate with improved artery stiffness in elderly hypertensive patients.

pharmacology & pharmacy,peripheral vascular disease
Effect of Valsartan on Elderly Hypertension

Febry Ardiana,Suciati,Gunawan Indrayanto

2010-01-01

Abstract:Aim To observe the effect of valsartan on elderly hypertension.Methods 58 cases of elderly inpatients with hypertension were randomly divided into treatment and control groups,treatment group added with oral valsartan.Results DBP,SBP of patients had significantly improved.There was a significant difference compared before treatment(P0.05),and treatment group improved significantly better than the control group(P0.05).Total effective rate of treatment group was 96.55%,significantly higher than the control group's 92.59%,with a significant difference(P0.05).Conclusion Valsartan treatment is safe,effective,which is an the ideal antihypertensive drugs for the elderly.
[Efficacy and Safety of Olmesartan Medoxomil Versus Losartan Potassium in Chinese Patients with Mild to Moderate Essential Hypertension].

Jun-ren Zhu,Nai-sheng Cai,Wei-hu Fan,Ding-liang Zhu,Ben He,Zong-gui Wu,Yuan-nan Ke,Jing-xuan Guo,Hong Ma,Jun Huang,Xin-li Li,Yun-zhen Chen

DOI: https://doi.org/10.3760/j:issn:0253-3758.2006.10.004

2006-01-01

Abstract:OBJECTIVE:To evaluate the efficacy and safety of olmesartan medoxomil compared with losartan potassium in patients with mild to moderate essential hypertension. METHOD:This is a randomized, double-blind, double-dummy, active-controlled, parallel, multi-center study. After a 2-week placebo run-in period, a total of 287 eligible subjects were randomized at 1:1 ratio to receive olmesartan medoxomil 20 mg or losartan potassium 50 mg, once daily for 8 weeks. The blood pressure was assessed after 4 weeks treatment. If the subject's seating diastolic blood pressure (SeDBP) was still >or=90 mm Hg, the dosage was doubled for another 4 weeks; for those subjects whose SeDBP was <90 mm Hg after 4-week treatment, the initial dosage remained unchanged and the treatment continued until completion of the study. RESULTS:(1) The mean trough reduction in SeDBP from baseline in olmesartan group was significantly greater than that in losartan group after 4 weeks (11.72 mm Hg vs 9.23 mm Hg, P=0.004) and 8 weeks treatment (12.94 mm Hg vs 11.01 mm Hg, P=0.035). (2) The number and percentage of responders in olmesartan group (81, 65.3%) were statistically higher than those (68, 52.7%) in losartan group (P=0.028) after 4 weeks treatment and were similar between the two groups after 8 weeks treatment (P>0.05). (3) Individual and overall trough/peak ratios of DBP and SBP in 24-hour ambulatory blood pressure monitoring were higher in olmesartan group than losartan group. The hypotensive effect of olmesartan was more durable than losartan at 24 hour interval. (4) The incidence of study drug-related adverse events (AEs) in olmesartan group (10.5%) was similar as that in losartan group (13.9%, P>0.05). Most of these AEs were mild and transient. CONCLUSION:This study shows that olmesartan medoxomil, at oral dose of 20 mg-40 mg once daily was effective and safe for hypertension treatment and the hypotensive effect was superior to losartan potassium (50 mg-100 mg once daily).
[Blood glucose determination for hospital screening with the autoanalyzer Clino-Mak].

S. Paal,A. Kazda,K. Mašek

1969-11-21

Abstract:
Efficacy of valsartan versus fosinopril in the treatment of aged patients with hypertension

De-xian WANG,Wei ZHAO,Yan-shu SUN,Qing-ping TIAN,Yan CHEN

DOI: https://doi.org/10.3321/j.issn:1003-3734.2005.03.030

2005-01-01

Abstract:Objective: To compare the efficacy and safety of valsartan versus fosinopril in the treatment of aged patients with mild to moderate hypertension. Methods: An unblended and parallelcontrolled study recruited 140 aged patients with mild to moderate hypertension, who randomly received either oral valsartan 80～160mg daily and oral fosinopril 10～40mg daily for 1 year. Ultrasound cardiography (UCG) and urinary albumin excretion rate (UAER) were measured before and after the 1-year treatment. Ambulatory blood pressure monitoring was performed before and after the 2-month treatment. Results:No significant differences in the overall response rate of valsartan and fosinopril(97. 0% vs. 96. 9 %) were found. After 1-year treatment with valsartan or fosinopril, both indices of left ventricular hypertrophy by UCG and UAER decreased,which showed statistical differences within the group(P0.05), but no difference between the two groups (P0. 05), respectively. No significant adverse events were reported in valsartan-treated patients but with 3 cases of severe cough in fosinopriltreated patients. Conclusion: Valsartan therapy can steadily control blood pressure,and show better tolerability in aged patients with mild to moderate hypertension.
Doxazosin in elderly patients with hypertension

M H Weinberger,A Fawzy

Abstract:Hypertension constitutes a major cardiovascular risk factor of high prevalence in the elderly, and reducing elevated blood pressure has been shown to be of significant benefit in decreasing the incidence of cardiovascular and cerebrovascular disease in this patient population. Elderly patients are more likely to have comorbid disorders, such as dyslipidaemia, diabetes, renal disease, atherosclerosis and, for males, benign prostatic hyperplasia (BPH). Therefore, when choosing an antihypertensive agent for elderly patients, it is particularly important to ensure that treatment does not exacerbate comorbid conditions and does not interact deleteriously with any concurrent medication that the patient is taking. The alpha 1-adrenoceptor antagonist, doxazosin, has been shown to be an effective, well-tolerated antihypertensive therapy in elderly male patients and does not exacerbate--and in some cases improves--some other common disorders. Doxazosin has been shown to be effective in reducing the symptoms of BPH in elderly patients whose blood pressure is well controlled by concomitant antihypertensive medication. In addition, improvements in the symptoms of BPH as well as reductions in blood pressure have been observed in elderly men with mild-to-moderate hypertension. Doxazosin has been shown to have positive effects on lipid profiles and glycaemic control, which make it an attractive choice of therapy for elderly patients with hypertension and diabetes or dyslipidaemia. In addition, doxazosin is administered once daily, either in the morning or the evening, which may aid compliance, an important consideration in the elderly.
Treatment strategies for isolated systolic hypertension in elderly patients

Fabio Angeli,Paolo Verdecchia,Sergio Masnaghetti,Gaetano Vaudo,Gianpaolo Reboldi

DOI: https://doi.org/10.1080/14656566.2020.1781092

2020-06-25

Expert Opinion on Pharmacotherapy

Abstract:Hypertension is a major and modifiable risk factor for cardiovascular disease. Its prevalence is rising as the result of population aging. Isolated systolic hypertension mostly occurs in older patients accounting for up to 80% of cases.The authors systematically review published studies to appraise the scientific and clinical evidence supporting the role of blood pressure control in elderly patients with isolated systolic hypertension, and to assess the influence of different drug treatment regimens on outcomes.Antihypertensive treatment of isolated systolic hypertension significantly reduces the risk of morbidity and mortality in elderly patients. Thiazide diuretics and dihydropyridine calcium-channel blockers are the primary compounds used in randomized clinical trials. These drugs can be considered as first-line agents for the management of isolated systolic hypertension. Free or fixed combination therapy with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and calcium-channel blockers or thiazide-like diuretics should also be considered, particularly when compelling indications such as coronary artery disease, chronic kidney disease, diabetes, and congestive heart failure coexist. There is also hot scientific debate on the optimal blood pressure target to be achieved in elderly patients with isolated systolic hypertension, but current recommendations are scarcely supported by evidence.

pharmacology & pharmacy
The Effects of Olmesartan on Ambulatory Blood Pressures and Blood Pressure Variability in Patients with Mild to Moderate Essential Hypertension

Jing Li,Tingli Qin,Hong Jiang,Hao Wang,Yuannan Ke

DOI: https://doi.org/10.3760/cma.j.issn.0578-1426.2014.10.007

2014-01-01

Abstract:OBJECTIVE:To evaluate the effect of olmesartan medoxomil tablets (olmesartan) in comparison with Olmetec on 24 h ambulatory blood pressure (ABPM) and blood pressure variability (BPV) in patients with mild to moderate hypertension.METHODS:A randomized, double-blind, double-mimic controlled trial was performed.Forty-eight patients with mild to moderate essential hypertension were randomly into treatment group (olmesartan) and control group (Olmetec) for eight weeks. The ABPM was taken before and at the end of the trial.RESULTS:After eight weeks, treatment with olmesartan induced a significant reduction in ABPM in patients [(9 ± 3)/(11 ± 3) mmHg(1 mmHg = 0.133 kPa)], which is similar with the reduction by Olmetec [(9 ± 4)/(9 ± 5) mmHg], P > 0.05. This situation holds for BPV with the standard deviations of 24 h, systolic blood pressure/diastolic blood pressure of pre-treatment and pro-treatment were (10 ± 2)/(11 ± 3) mmHg vs (10 ± 3)/(12 ± 2) mmHg in olmesartan group, and (10 ± 3)/(11 ± 3) mmHg vs (12 ± 3)/(12 ± 4) mmHg in Olmetec group. (3) There is no difference in the rate of adverse event between olmesartan (10.42%) and Olmetec (8.33%) treatment (P > 0.05).CONCLUSION:Similar to Olmetec, treatment with olmesartan once daily can significantly reduce ABPM in patients with mild to moderate essential hypertension.
DiffErenCes in AntihypertenSive Drug Blood Levels in Patients with HypertensiON (DECISION): Protocol for a Prospective Observational Study Comparing Pharmacokinetics and Pharmacodynamics Between Young and Elderly Patients

Dimokrat Hassan,Laura E. J. Peeters,Birgit C. P. Koch,Jorie Versmissen

DOI: https://doi.org/10.1007/s40292-022-00505-w

2022-02-17

Abstract:Adequate controlled blood pressure decreases the risk of cardiovascular events. However, the elderly are more vulnerable and thereby more prone to side effects of antihypertensive drugs. A lack of pharmacokinetic and pharmacodynamic (PK/PD) studies in older patients makes specific and tailored advices towards antihypertensive drug therapy difficult. The aim of our study, DiffErenCes In antihypertenSive drug levels In patients with hypertensiON (DECISION), is to fill in this PK/PD knowledge gap and move towards precision dosing. DECISION is a prospective observational PK/PD study set up to determine the difference in exposure to the antihypertensive drugs, losartan and perindopril, measured by drug levels in blood. The area under the curve (AUC; PK) and furthermore the association between the AUC and the effect on blood pressure (PD) will be compared between elderly and younger patients.
The Clinical Efficacy and Safety of Valsartan in Treatment of Patients with Essential Hypertensive

刘忠,陈君柱,朱建华,徐耕,黄慧芳,徐绍彦,钱宝庆

DOI: https://doi.org/10.3969/j.issn.1006-2785.2003.07.006

2003-01-01

Abstract:Objective To investigate the efficacy and safety of valsartan in treatment of essential hyˉpertensive patients.Methods Seventy three patients with essential hypertension received valsartan80mg daily for8weeks;for some non-responded patients hydrochlorothiazide(12.5mg/25mg daily)was added.Results Valsartan reduced sitting blood pressure from(156.43±10.46)/(95.76±3.79)mmHg to(134.56±9.15)/(82.38±6.01)mmHg(t=19.020,18.983,P0.001).Meanwhile standing blood pressure was reduced from(154.54±11.06)/(94.37±4.67)mmHg to(133.75±9.40)/(81.76±6.00)mmHg(t=16.584,17.169,P0.001),and no patient had orthostatic hypotension caused by valsartan.The effective rate of valsartan was77.78%.Valsartan also reduced proteinuria.Conclusions In mild-moderate essential hypertensive patients,Valsartan was effective and well tolerated and offers a promising approach to the treatment of hypertension.
Long-Term Efficacy of Olmesartan Medoxomil in Chinese Hypertensive Patients As Assessed by Clinic, Ambulatory and Home Blood Pressure Measurements

Ji-Guang Wang,Ning-Ling Sun,Yuan-Nan Ke,Bo-Heng Zhang,Naotaka Ikegami,Jun-Ren Zhu

DOI: https://doi.org/10.1007/s40261-012-0003-7

2012-01-01

Clinical Drug Investigation

Abstract:There is limited information on the long-term efficacy and safety of olmesartan medoxomil in the management of hypertension in Chinese patients. We therefore conducted the present multicentre, single-arm, prospective, observational study to investigate the 24-week efficacy and safety of olmesartan medoxomil in patients with mild to moderate hypertension.
Rationale and Design of a Randomized, Open‐Label, Parallel‐Group Study of Esaxerenone Versus Angiotensin Receptor Blockers in Older Patients With Uncontrolled Hypertension on Calcium Channel Blocker Monotherapy (ESCORT‐HT)

Kazuomi Kario,Tomohiro Katsuya,Tatsuo Shimosawa,Takashi Taguchi,Ayumi Tanabe,Mitsuru Ohishi,the ESCORT‐HT investigators

DOI: https://doi.org/10.1111/jch.14947

2024-11-29

Journal of Clinical Hypertension

Abstract:Angiotensin II receptor blockers (ARBs) and calcium channel blockers (CCBs) are commonly prescribed as first‐ and second‐line treatments for older Japanese patients with hypertension. However, due to age‐related decline in renin activity, the effectiveness of ARBs may decrease. This highlights the need for other antihypertensive agents to be used in combination with CCBs to replace ARBs for more effective blood pressure (BP) control. The ESCORT‐HT study is a multicenter, randomized, controlled, open‐label, parallel‐group study with a 4‐week run‐in period and 12‐week treatment period. This study aims to evaluate the efficacy of esaxerenone as a second‐line treatment for hypertension and to determine whether its BP‐lowering effect is noninferior to that of ARBs in older patients with uncontrolled hypertension on CCB monotherapy. The safety profiles of esaxerenone and ARBs will also be evaluated. Patients will be randomly assigned in a 1:1 ratio to receive either esaxerenone or an ARB. The primary efficacy endpoint will be the change from baseline in morning home systolic BP at the end of the treatment period. The BP‐lowering effect of esaxerenone will be considered noninferior to that of ARBs if the upper limit of the two‐sided 95% confidence interval (CI) for the difference in systolic BP change between esaxerenone and ARB is <3.8 mmHg, and will be considered superior if the upper limit of the two‐sided 95% CI is <0. The findings may elucidate the possible benefits of earlier use of mineralocorticoid receptor blockers in combination with CCBs in older patients with essential hypertension.

peripheral vascular disease
Hypertension Management in Older and Frail Older Patients

Athanase Benetos,Mirko Petrovic,Timo Strandberg

DOI: https://doi.org/10.1161/CIRCRESAHA.118.313236

IF: 23.213

2019-10-07

Circulation Research

Abstract:The prevalence of arterial hypertension, particularly systolic hypertension, is constantly rising worldwide. This is mainly the clinical expression of arterial stiffening as a result of the population's aging. Chronic elevation in blood pressure represents a major risk factor not only for cardiovascular morbidity and mortality but also for cognitive decline and loss of autonomy later in life. Clinical evidence obtained in community-dwelling older people with few comorbidities and preserved autonomy supports the beneficial effects of lowering blood pressure in older hypertensive subjects even after the age of 80 years. However, observational studies in frail older individuals treated for hypertension have shown higher morbidity and mortality rates compared with those with lower blood pressure levels. Clearly, in very old subjects, the therapeutic strategy of one size fits all cannot be applied because of the enormous functional heterogeneity in these individuals. Geriatric medicine proposes taking into account the function/frailty/autonomy status of older people. In the present review, we propose to adapt the antihypertensive treatment using an easy-to-apply visual numeric scale allowing the identification of 3 different patient profiles according to the functional status and autonomy for activities of daily living. For the preserved function profile, strategies should be those proposed for younger old adults. For the loss of function/preserved activities of daily living' profile, a more detailed geriatric assessment is needed to define the benefit/risk balance as well as requirements for the tailoring of the various therapeutic strategies. Lastly, for the loss of function and altered activities of daily living' profile, therapeutic strategies should be thoroughly reassessed, including deprescribing (when considered appropriate). In the near future, controlled trials are necessary for the most frail older subjects (ie, in those systematically excluded from previous clinical trials) to gain stronger evidence regarding the benefits of the various therapeutic strategies.

cardiac & cardiovascular systems,peripheral vascular disease,hematology
Pharmacokinetic and pharmacodynamic considerations in the treatment of the elderly patient with hypertension

L.E.J. Peeters,M.P. Kester,L. Feyz,P.M.L.A. Van Den Bemt,B.C.P. Koch,T. Van Gelder,J. Versmissen

DOI: https://doi.org/10.1080/17425255.2019.1588249

2019-03-16

Abstract:INTRODUCTION: Hypertension is an important risk factor for developing cardiovascular diseases. It is more prevalent in the elderly population. Recently updated American and European guidelines recommend treating every elderly patient with hypertension independent of age, starting with a low dose of antihypertensive drugs. However, little information is available on the optimal dosages of antihypertensive drugs to treat the elderly safely. Areas covered: Comorbidities, co-medication and frailty status can alter the clinical outcome of drug treatment and can cause adverse events in the elderly. Also, due to pharmacokinetic and pharmacodynamic changes the interpatient variability when using antihypertensive drugs is considerable. In this review, an overview is given on the extent to which the previously mentioned parameters are changed in elderly patients and what this means for the exposure to antihypertensive medication. Also, recommendations on the starting dose of the most frequently used antihypertensive drugs are given based on literature data. Expert opinion: We believe that recommendations on starting dosages followed by a stepwise increase of dosages will lead to improved blood pressure control and less adverse drug reactions in the elderly patient. This may improve adherence to antihypertensive therapy.

pharmacology & pharmacy,biochemistry & molecular biology,toxicology
Efficacy and Safety of Sacubitril/valsartan Compared with Olmesartan in Asian Patients with Essential Hypertension: A Randomized, Double-Blind, 8-Week Study.

Yong Huo,Weimin Li,Randy Webb,Li Zhao,Qian Wang,Weinong Guo

DOI: https://doi.org/10.1111/jch.13437

2018-01-01

Abstract:This study assessed the efficacy and safety of angiotensin receptor neprilysin inhibitor sacubitril/valsartan vs olmesartan in Asian patients with mild-to-moderate hypertension. Patients (N = 1438; mean age, 57.7 years) with mild-to-moderate hypertension were randomized to receive once daily administration of sacubitril/valsartan 200 mg (n = 479), sacubitril/valsartan 400 mg (n = 473), or olmesartan 20 mg (n = 486) for 8 weeks. The primary endpoint was reduction in mean sitting systolic blood pressure (msSBP) from baseline with sacubitril/valsartan 200 mg vs olmesartan 20 mg at Week 8. Secondary endpoints included msSBP reduction with sacubitril/valsartan 400 mg, and reductions in clinic and ambulatory BP and pulse pressure (PP) vs olmesartan. In addition, changes in msBP from baseline in the Chinese subpopulation, elderly (>= 65 years), and in patients with isolated systolic hypertension (ISH) were assessed. Sacubitril/valsartan 200 mg provided a significantly greater reduction in msSBP than olmesartan 20 mg at Week 8 (between-treatment difference: -2.33 mm Hg [95% confidence interval (CI) -4.00 to -0.66 mm Hg], P < 0.05 for non-inferiority and superiority). Greater reductions in msSBP were also observed with sacubitril/valsartan 400 mg vs olmesartan 20 mg (-3.52 [-5.19 to -1.84 mm Hg], P < 0.001 for superiority). Similarly, greater reductions in msBP were observed in the Chinese subpopulation, in elderly patients, and those with ISH. In addition, both doses of sacubitril/valsartan provided significantly greater reductions from baseline in nighttime mean ambulatory BP vs olmesartan. Treatment with sacubitril/valsartan 200 or 400 mg once daily is effective and provided superior BP reduction than olmesartan 20 mg in Asian patients with mild-to-moderate hypertension and is generally safe and well tolerated.

Olmesartan Medoxomil in Elderly Patients with Essential or Isolated Systolic Hypertension

Clinical Study of Olmesartan/hydrochlorothiazide Compound Tablet in Mild to Moderate Essential Hypertensive Patients Who Did Not Reach Goal with Olmesartan

Efficacy and Safety of Sacubitril/Valsartan (LCZ696) Compared with Olmesartan in Elderly Asian Patients (≥65 Years) with Systolic Hypertension.

Efficacy and Safety of Olmesartan Medoxomil‑amlodipine Besylate Tablets (sevikar®) in Older Patients with Essential Hypertension: Subgroup Analysis from the Sevikar Study.

Efficacy and Safety of Olmesartan Medoxomil-Amlodipine Besylate Tablet in Chinese Patients with Essential Hypertension: A Prospective, Single-Arm, Multi-Center, Real-World Study

Efficacy of Olmesartan/Amlodipine Single‐Pill Combination on 24‐h Mean Systolic Blood Pressure Measured by Ambulatory Monitoring in Non‐Responders to Valsartan or Candesartan Monotherapy

The association between oxidative stress, activator protein-1, inflammatory, total antioxidant status and artery stiffness and the efficacy of olmesartan in elderly patients with mild-to-moderate essential hypertension

Effect of Valsartan on Elderly Hypertension

[Efficacy and Safety of Olmesartan Medoxomil Versus Losartan Potassium in Chinese Patients with Mild to Moderate Essential Hypertension].

[Blood glucose determination for hospital screening with the autoanalyzer Clino-Mak].

Efficacy of valsartan versus fosinopril in the treatment of aged patients with hypertension

Doxazosin in elderly patients with hypertension

Treatment strategies for isolated systolic hypertension in elderly patients

The Effects of Olmesartan on Ambulatory Blood Pressures and Blood Pressure Variability in Patients with Mild to Moderate Essential Hypertension

DiffErenCes in AntihypertenSive Drug Blood Levels in Patients with HypertensiON (DECISION): Protocol for a Prospective Observational Study Comparing Pharmacokinetics and Pharmacodynamics Between Young and Elderly Patients

The Clinical Efficacy and Safety of Valsartan in Treatment of Patients with Essential Hypertensive

Long-Term Efficacy of Olmesartan Medoxomil in Chinese Hypertensive Patients As Assessed by Clinic, Ambulatory and Home Blood Pressure Measurements

Rationale and Design of a Randomized, Open‐Label, Parallel‐Group Study of Esaxerenone Versus Angiotensin Receptor Blockers in Older Patients With Uncontrolled Hypertension on Calcium Channel Blocker Monotherapy (ESCORT‐HT)

Hypertension Management in Older and Frail Older Patients

Pharmacokinetic and pharmacodynamic considerations in the treatment of the elderly patient with hypertension

Efficacy and Safety of Sacubitril/valsartan Compared with Olmesartan in Asian Patients with Essential Hypertension: A Randomized, Double-Blind, 8-Week Study.